Functional analysis of coding and non-coding RNA usually involves the use of antisense oligonucleotides (ASO) for specific inhibition or knockdown of RNA targets in vitro and in vivo. Locked Nucleic Acids or LNA™-enhanced ASOs offer simple and efficient approaches for the study of RNA function and due to their high biological stability and activity, hold promising potential in therapeutic applications.
Exiqon offer highly potent LNA™ microRNA inhibitors and target site blockers as well as LNA™ GapmeRs for silencing mRNA and long non-coding RNA. Our comprehensive product range includes ASOs ideal for both in vitro and in vivo use.
In Vivo Guidelines
Read about the key technologies enabling functional analysis of microRNA, mRNA and lncRNA in animal models. Topics include routes of administration, pharmacokinetics and biodistribution of antisense oligonucleotides. We also describe how to establish the optimal dose regime. Download In Vivo Guidelines
Development of antisense therapy for cystic fibrosis
Dr. Magali Taulan is an associate professor at the University of Montpellier in France. Her lab has been using LNA™ antisense oligonucleotides that interfere with microRNAs to better understanding how CFTR expression is regulated.
OncomiR screening using Exiqon's microRNA Inhibitor Library
A recent paper published by Micol Fiori et al. describes the use of Exiqon's microRNA library to screen for oncomiRs as therapeutic targets for treatment of lung cancer. One of the targets hsa-miR-197 was studied in detail.
Read the full paper
mRNA silencing in vitro and in vivo using LNA™ GapmeRs
Anastasia Khvorova works at the RNA Therapeutics Institute at the University of Massachusetts Medical School. Her lab has been using LNA™ GapmeRs to silence two different genes which are valid therapeutic targets for neurodegenerative diseases.
New microRNA mimics
Our sophisticated new 3rd generation microRNA mimics are ideal for simulating naturally occurring microRNAs. They feature an innovative triple RNA strand design which ensures that only the microRNA strand is loaded into the RISC complex, with no activity from the passenger strands. Read more
In vivo inhibition of lncRNA
Katharina Michalik, Reinier Boon and Stefanie Dimmeler at Goethe University in Frankfurt are interested in microRNAs and long non-coding RNAs that control cardiovascular functions in endothelial cells. They have been using LNA™ GapmeRs to silence Malat1 in vitro and in vivo. Read more
Our microRNA inhibitors just got better
Our miRCURY LNA™ microRNA Inhibitors and Power Inhibitors have been completely redesigned and updated to miRBase 20. We offer pre-designed inhibitors for virtually all human, mouse and rat in miRBase. Custom inhibitors are available for all other organisms. Read more
Featured article: miRNome-wide functional analysis
In a recent article published in PLOS ONE, Polesskaya and colleagues used a microRNA inhibitor library screen to discover and validate 63 microRNAs involved in muscle cell differentiation. The authors of this seminal paper present a novel strategy that can facilitate the functional annotation of the human miRNome. Read the paper
Free webinar: advances in gene silencing and lncRNA research
Join this free webinar to learn about: The new advanced tools for potent gene silencing in vitro and in vivo. The challenges of inhibiting long non-coding RNA and how to overcome them. The essentials of a successful RNA knockdown experiment using LNA™ GapmeRs. See it on demand
Free Science/AAAS Webinar: Targeting non-coding RNA in disease
Listen to Dr. Stephanie Dimmeler, Dr. Jan-Wilhelm Kornfeld and Dr. David Corey present the following topics: non-coding RNAs as therapeutic targets in human disease, the unique challenges of targeting functional RNA in vivo and recent advances enabling effective in vivo inhibition of non-coding RNA. See it on demand
5 tips for setting up a successful RNA inhibition experiment using gapmers
What is most important to consider when setting up an RNA silencing experiment? How can you increase the chances of success? We have gathered the top tips for inhibition of mRNA and lncRNA using LNA™ GapmeRs.
View the tips
Inhibition of microRNA function: Challenges and opportunities
This webinar focuses on the challenges of microRNA inhibition and how to overcome them, the essentials of a successful microRNA inhibition experiment and the opportunities for analyzing microRNA function in vivo.
View the webinar
Top 5 tips for successful microRNA inhibition
MicroRNA inhibition is a powerful technique for determining the function of a microRNA. Here, we have assembled five important tips for successful silencing experiments.
Free Nature reprint collection: microRNA from bench to clinic
This Nature Reprint Collection presents some of the recent advances in moving microRNAs from basic research into the clinic both as diagnostic biomarkers and therapeutic targets. Three of the articles focus on the potential of microRNAs as therapeutic targets in cardiovascular disease, diabetes and epilepsy. Get your free copy
Inside story: GapmeRs to silence lncRNA
Drs. Jean-Christophe Marine, Eleonora Leucci and Laura Standaert work at the Laboratory for Molecular Cancer Biology, K.U. Leuven in Belgium. They have been using LNA™ longRNA GapmeRs to silence non-coding RNAs linked to cancer.
Read about their exciting research
Sophisticated LNA™ GapmeR design tool online
The advanced algorithm behind our highly successful gapmers is now available in an easy to use online tool. Use it to design potent antisense oligonucleotides for your mRNA or lncRNA target.
Try the tool
Solving the mystery of an unknown target gene with microRNA TSBs
Dr. Virgine Mattot works in the team “Angiogenesis, endothelium activation and Cancer” directed by Dr. Fabrice Soncin at the Institut de Biologie de Lille. She has been using Target Site Blockers to investigate the role of microRNAs on putative targets which functions are yet unknown. Read about their exciting research
microRNA inhibitors and target site blockers
Find out more about our miRCURY LNA™ microRNA Inhibitor and Target Site Blockers based on the LNA™-technology for superior specificity and biostability.